Oric Pharmaceuticals Inc at Guggenheim Healthcare Talks Biotechnology Conference Transcript

Feb 07, 2024 / 03:00PM GMT
Michael Schmidt - Guggenheim - Analyst

All right. Great. So welcome to this fireside chat with Arctic. My name is Michael Schmidt. I'm a biotech analyst with Guggenheim. I'm pleased to welcome Dominic Prisca, Tele CFO, and Matt kind of up on Panamax.

Questions and Answers:

Michael Schmidt - Guggenheim - Analyst

Sorry, CVO. Welcome, guys. Thanks for joining us on. So Dominic, just a high-level question to start out with you guys have three clinical stage oncology programs now in the pipeline and are each of them pursuing different targets and pathways? Can you just remind us of your general pipeline strategy and how you select your programs?

Dominic Piscitelli - Oric Pharmaceuticals Inc - Chief Financial Officer

Yes. Sure. So first of all, thank you for having us here at the conference and the opportunity to present today. So Orange is a clinical-stage oncology company. Our name really encapsulates our overall mission, which is to overcome resistance in cancer.

With regards to our strategy around
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot